Our TeamA new class of therapies to treat cardiovascular diseases
Bhawanjit Brar Ph.D.
Co-Founder and Chief Executive Officer
Dr. Brar founded Jaan Biotherapeutics in 2015, following 7 years at Zensun USA, where she held various positions including the Vice President of Clinical Research, managing a United States Phase 2 clinical trial for a first in class therapeutic for the treatment of heart failure. Dr. Brar completed her undergraduate degree in Biochemistry from Swansea University in Wales and a Ph.D. in Physiology/Endocrinology from the University of Reading U.K. Dr. Brar has served as a consultant for many years helping companies to develop therapeutics through to clinical testing before founding Jaan Biotherapeutics. Dr. Brar is an inventor/co-inventor of numerous patents. In her spare time Dr. Brar like to spend time with her teenage daughters, walking her rescue American Staffordshire Terrier, cooking and running. She serves on the Board of Directors of her community as well as a member of the Women in Biosciences Founders Forum Group.
Kirk L. Peterson, M.D., F.A.C.P., F.A.C.C.
Professor of Medicine, Division of Cardiovascular Medicine, Director Emeritus, Sulpizio Cardiovascular Center, Director, Seaweed Canyon Physiology Laboratory
Kirk L. Peterson, MD, FACP, FACC, is a Professor of Medicine Emeritus at the University of California San Diego (UCSD) School of Medicine where he held the Perlman Chair of Cardiology for more than 25 years. During his 50-year professional career at UCSD, he also served as a cardiology consultant to the Naval Regional Medical Center and the Veteran’s Hospital in San Diego. He served as the Director of the Sulpizio Cardiovascular Center, UC San Diego Health System, from its opening in 2011 until 2015. During his academic career he sat on the editorial board of the Journal American College of Cardiology and was also President of the Medical Education Research Foundation. Between 2005 and 2020, Professor Peterson served as the Director of the Seaweed Canyon Cardiovascular Physiology Laboratory, University of California at San Diego School of Medicine, the site where the murine investigations of Jaan Biotherapeutics drugs were conducted in double-blind studies. He has authored over 180 papers in cardiology, numerous book chapters, and served as the senior author of a text book on Cardiac Catheterization and Angiography. Professor Peterson received his medical degree from the Cornell University Medical College in New York, New York,completed two years of post-graduate training in Internal Medicine at The New York Hospital-Cornell Medical Center, and received fellowship training in Cardiovascular Medicine at The Baylor College of Medicine before coming to UC San Diego.
Co-Founder, Chief Financial Officer
Joseph Hansen, CPA/Attorney, is Chief Financial Officer of JaanBiotherapeutics LLC and a member of the City of Oceanside Citizen Oversight Investment Committee. He formerly was CFO for a number of public and private companies including Zensun Science and Technology Co., Ltd Shanghai, PRC, Pacific Ethanol, Inc. (Nasdaq), National RV Holdings, Inc. (formerly NYSE), Zacky Foods/Farms Companies, Avis Enterprises/Intervest (holding companies of Warren Avis, Avis Rent a Car founder), among others. He is co-founder of 4 companies and a former board member of private companies. His early background consisted of employment with Big 4 accounting firms, the practice of law, and editing for the Journal of Taxation. He holds degrees from New York University Graduate School of Law-LLM-Tax, Tulane University School of Law-JD, and University of Wisconsin-Madison-BBA accounting. He also holds a Wisconsin Bar license-inactive and an inactive CPA license.
Marcus Bobar BS
Marcus has developed efficient techniques to consistently acquire accurate in-vivo cardiac Magnetic resonance (MR) imaging data, a robust image analysis pipeline, and novel methods to determine regional function in the beating heart. As the prior head of the MR core for the Department of Cardiology at the University of California, San Diego, Marcus collaborated with many investigators executing MR studies for projects, including the application of machine learning for clinical cardiac image analysis and developing high-resolution ex-vivo MR methods determining tissue composition. Mr. Bobar, received his Bachelors of Science degree from the University of California, San Diego in Biochemistry and Cell Biology. In addition to working at JaanBiotherapeutics as their imaging scientist, he is also a Ph.D. candidate at the University of Virginia.
Advisors and Consultants
Barry H. Greenberg, MD
Distinguished Professor of Medicine- Director, Advanced Heart Failure Treatment Program-UCSD Medical Center
Barry H. Greenberg, MD, is Distinguished Professor of Medicine and Director of the Advanced Heart Failure Treatment Program at the University of California, San Diego (UCSD). After an internal medicine residency at Yale-New Haven Hospital, research training at the Lipid Metabolism Branch of the NHLBI and a fellowship in cardiology at UCSF, he joined the faculty of Oregon Health Sciences University School of Medicine. Dr. Greenberg has been a visiting professor in residence at the Royal Postgraduate Medical School in London, England and at the Laboratoire de MédicineExpérimentale of the Collège de France in Paris. Dr. Greenberg’s research focuses on mechanisms of cardiac dysfunction and developing new heart failure therapies. He has served in the leadership of numerous international multicenter heart failure trials. In addition, Dr. Greenberg directs a laboratory that studies the molecular basis of cardiac remodeling and myocardial fibrosis. Dr. Greenberg is co-editor of Congestive Heart Failure: Pathophysiology, Diagnosis, and Comprehensive Approach to Management, the first comprehensive text in this field and he is a member of the editorial boards of several cardiology and subspecialty journals including JACC: Heart Failure and the European Journal of Heart Failure. Dr. Greenberg is a founding member and past President of the Heart Failure Society of America (HFSA). He has been recognized for many years as being one of the “Best Doctors in America” and “Best Doctors in San Diego.” Dr. Greenberg received the HFSA’s Lifetime Achievement Award in 2017.
Andreas Bader Ph.D.
Dr. Andreas Bader is SVP of R&D at Triumvira and has more than 20 years’ experience in oncology drug discovery and development. Previously, Dr. Bader acted as Co-Founder and CEO of Orros Biotherapeutics LLC, and as a scientific Co-Founder of Mirna Therapeutics, Inc., where he held multiple leading positions in R&D and led research programs from discovery to the completion of the MRX34 Phase 1 clinical trial, the first miRNA mimic ever to enter clinical testing. Prior to Mirna, Dr. Bader functioned as a Scientific Lead at Asuragen, Inc. Dr. Bader completed his post-doctoral training at The Scripps Research Institute, La Jolla, California, and received his Ph.D. in Biochemistry and his MSc degree in Biology from the University of Innsbruck, Austria.
Stanley A. Roberts, Ph.D.
Stan Roberts is an independent consultant in toxicology, drug metabolism (ADME), pharmacokinetics (PK) and drug development. He has over 35 years of experience in scientific and management positions in large (Sandoz, Abbott & Pfizer) and small (CovX) pharmaceutical companies. His management duties have included being the Global Director for Preclinical ADME/PK at Abbott for over eight years. Stan has also held a variety of leadership positions in toxicology organizations for over 20 years. For preclinical scientific strategy and operations, he has planned, conducted, interpreted and reported all types of toxicology (i.e., mechanism of toxicity, acute, dermal, ocular, ISO compliant medical device, sub chronic, chronic and carcinogenicity) and ADME/PK studies. Stan has created development plans and strategies for many types of pharmaceuticals including numerous classes of small molecules, proteins, monoclonal antibodies, antibody drug conjugates, peptides, nucleotides, glycosaminoglycan’s, medical devices and stem cell therapies.
Accomplishments include authoring over 400 internal final reports, major contributions to numerous successful regulatory documents/strategies/submissions (white papers, IND & NDA) and conducting problem solving research that evaluated the human relevance of animal toxicities as well as ADME/PK challenges. Stan has a BS (Animal Science), MS and Ph.D. (Pharmacology & Toxicology) from Purdue and post-doctoral fellowship in Molecular Toxicology (Medical University of South Carolina).
Shirley Cao MS.
Quality, Chemistry and Manufacturing and Controls
Chemistry manufacturing and controls (CMC) is an integral and important part of the development for any new therapeutic product or treatment. With more than twenty years of pharmaceutical/biotechnology industry experience in Quality Assurance, Quality Control and Development. With over 25 years of experience, Ms. Cao has an excellent understanding of multi-country regulatory requirements in CMC for bringing new product or therapy from laboratory bench to human clinical trials, and in-depth knowledge and expertise in all aspects of CMC and a major contributor for CMC sections US and foreign IND filings. Ms. Cao received her Bachelor’s degree in Chemistry from Zhengzhou University and her Master’s degree from Wuxi Institute of Light Industry (now Jiangnan University) in Food Science and technology.
Louis Scotti, BS
Louis Scotti has headed business development, marketing, new products and investor/public relations functions during a long career in the bio/pharma industry both in the U.S. and internationally. His appointments include VP Business Development (IRISYS LLC), Chief Business Development Officer (Druggability Technologies), VP Commercial Planning/Business Development/Marketing (Arena Pharmaceuticals), Executive Director Licensing (Ligand Pharmaceuticals) and Product Manager (Bristol-Myers). He was a member of the board of directors for IRISYS Inc. from 2007 – 2012. During his career, he identified, negotiated and closed over 50 partnerships, R&D collaborations, licenses and commercialization agreements for biotech and pharmaceutical companies on both the buy and sell-side. He holds a B.S.E in Biomedical Engineering from the University of Pennsylvania and is a Certified Licensing Professional.
Stephane Richard is US Director of Business Development for the Integrated Drug Discovery Services of Oncodesign, a French Biopharmaceutical company. Previously, Stephane led CureMatch Inc., a precision oncology startup, acting as first CEO, as well as President & COO, translating an academic research project into a funded biotech supporting oncologists in their commitment to improve the duration and quality of life of cancer patients. Prior to CureMatch, Stephane had founded and managed French BioBeach, an organization promoting biotech business development between Southern California and European Life science groups while collaborating with numerous French & US biotech. Author of 18 peer-reviewed scientific papers and 6 patents, Stephane received a Ph.D. in protein crystallography from the University Joseph Fourier in Grenoble, and an M.S. in biophysics from the University of Marseille, France. Stephane has been a scientist at the Salk Institute for Biological Studies and at Sapphire Energy, before holding managerial positions in biotech.
Scott Garrett MBA
Scott Garrett has deep experience in cardiovascular therapeutics, including gene therapy and regenerative medicine. Advanced experience in Commercial Strategy, Analytics, Clinical Marketing, Market Access and Health Economics. Scott has held executive roles with Scios (acquired by J&J), CV Therapeutics (acquired by Gilead), Cadence Pharmaceuticals (acquired by Mallinckrodt) and Portola Pharmaceuticals (acquired by Alexion Pharmaceuticals).
Jing Liu Ph.D., JD.
Experienced Life Science Technologies and IP Attorney and partner at Sheppard Mullin in the firm’s San Diego office.
Sandeep Birdi JD. MSc.
Founder of CrossPond Law. European patent attorney and a Chartered UK patent attorney. Mr. Birdi is a graduate of the University of Leeds obtaining a first class honors Master’s degree in chemistry.
Jim Krenn, JD
Jim is a partner at Morrison & Foerster and has extensive experience representing private and public companies and investors in significant business transactions from formation through liquidity. His practice focuses on mergers and acquisitions, venture capital financing, and emerging company counseling. Jim received his bachelor’s degree from the University of Notre Dame and his JD from Harvard University.